Kathleen Tregoning serves as Executive at Spero Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Kathleen Tregoning has executed 7 insider transactions totaling $260.4K, demonstrating a bearish approach to their equity position. Their most recent transaction on Aug 1, 2024 involved selling 10,666 shares valued at $0.
Kathleen Tregoning currently holds 55,000 shares of Spero Therapeutics, Inc. (SPRO), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kathleen Tregoning has been a net seller of SPRO stock. They have purchased $0 and sold $260.4K worth of shares.
Kathleen Tregoning's most recent insider trade was on Aug 1, 2024, when they sold 10,666 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Dec 26, 2023 | CERE | $31.7K | Option Exercise | 3,150 | $10.05 | Discretionary |
| Dec 20, 2023 | CERE | $260.4K | Sale | 6,288 | $41.42 | Discretionary |
| Dec 19, 2023 | CERE | $0 | Option Exercise | 13,804 | $N/A | Discretionary |
| Oct 5, 2023 | SPRO | $0 | Award | 20,000 | $N/A | Discretionary |
| Sep 15, 2022 | SPRO | $0 | Award | 15,000 | $N/A | Discretionary |